Investing in Japan
Investment Promotion in Osaka’s Growing Industry Sector-Formation of a Medical Cluster centered on the National Cerebral and Cardiovascular Center-
Jul 24, 2015
Osaka aims to be one of the best centers for life innovation in the world taking advantage of deregulation in the National Strategic Special Zone and projects by the Kansai Innovation International Strategic Comprehensive Special Zone. The Osaka Investment Promotion Seminar was held on June 24 in Tokyo under the main theme of forming a medical cluster centered on the National Cerebral and Cardiovascular Center (NCVC), which expects relocation and expansion not later than 2018, as well as open innovation.
Kansai as a center medical innovation -Taking advantage of special zones
With the two approved special zones in its region, one being the National Strategic Special Zone and the other being the Kansai Innovation International Strategic Comprehensive Special Zone, the Kansai region is implementing deregulation and tax incentives in the life science sector within those special zones.
The Kansai region is also utilizing the national support system for the Kansai Innovation International Strategic Comprehensive Special Zone in undertaking the establishment of the Kansai Branch of the Pharmaceuticals and Medical Devices Agency (PMDA) development on which JTEC Corporation is working in Saito, north of Osaka, and the research and development aimed at putting regenerative medicine and cell therapy into practical application as soon as possible. The number of projects approved in the Kansai Innovation International Strategic Comprehensive Special Zone amounts to 49, recording the largest number in the nation, and 35 cases of those projects are related to the life science sector.
In Osaka Prefecture, in close alignment with the system of the Kansai Innovation International Strategic Comprehensive Special Zone, the best and first tax incentive of its kind in Japan is being offered: zero local taxes.
In the National Strategic Special Zone, Osaka is also taking the initiative in deregulating drugs. For therapeutic drugs that have already obtained approval as medicine for cardiac arrest through research by NCVC, the time required to also approve them as off-label drugs for other usage in the treatment of preventing cancer metastases and suppressing cancer at hospitals after cancer surgeries has been shortened from the usual six months to three.
Formation of a new medical cluster centered on NCVC
According to the relocation and expansion plan underway, the 10,000 m2 Open Innovation Center will be created with staff posted at NCVC specializing in intellectual property and pharmaceutical law to create an environment that promotes discussions with special doctors and researchers without hesitation as well as to achieve existing missions. In addition, the approximately four-hectare KENTO Innovation Park will also be developed in the vicinity of the NCVC to attract companies related to life science with the keywords of “health” and “medical care”.
Osaka's initiatives in 2015
The Osaka Bio Strategic Promotion Conference, which is composed of executives and top management of leading companies, universities and municipalities of Osaka that represent the life science sector in Shin-Osaka, draws up action plans based on the“Osaka Bio Strategy” and updates them every year. To establish Osaka as well as the greater Kansai region as a center of medical innovation, the Osaka Bio Strategic Promotion Conference is making steady progress with this cooperative framework consisting of industry, academia and government throughout Osaka in the following initiatives: formation of a medical cluster, bolstering support for research and development, promotion of commercialization and venture companies. It is doing this by taking advantage of regulatory reforms by the National Strategic Special Zone and other zones, making the best use of support functions by the Japan Agency for Medical Research and Development (AMED) and the Kansai Branch of the Pharmaceuticals and Medical Devices Agency (PMDA), building clinical research networks with the cooperation of fifteen core medical institutions in Osaka.